Filter
383
Text search:
Foundation
for
Innovative
and
New
Diagnostics
Featured
42
93
Language
Document type
169
93
47
33
24
9
4
3
1
Countries
36
12
10
10
7
7
7
6
6
5
5
5
4
4
4
4
4
4
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
92
34
27
22
10
8
4
Toolboxes
84
36
32
23
20
18
15
14
9
8
8
7
6
5
5
5
3
2
2
1
1
1
1
Accessed on 04.04.2023
The Drugs for Neglected Diseases initiative (DNDi) is an international
non-profit organization that discovers, develops, and delivers safe,
effective,
...
This report examines the support to private healthcare provision in India by the World Bank’s private sector arm, the International Finance Corporation (IFC). Despite supporting private healthcare in the country since 1997, no healthcare results for
...
This National Action Plan addresses actions needed to be taken in order to combat antimicrobial resistance (AMR) in the country. It is obligatory to raise awareness of antimicrobial resistance and promote behavioral change through public communicati
...
The WHO End TB Strategy aims to end the global TB epidemic by 2030, in alignment with Goal 3 of the United Nations (UN) Sustainable Development Goals (SDGs). Member States of the World Health Organization (WHO) and the UN committed to ending the TB
...
The five hepatitis viruses have different epidemiological profiles, and their impact, duration, and transmission route also vary. The most common transmission routes contributing to the spread of he
...
В сборнике представлены статьи специалистов в сфере охраны психического здоровья по различным академическим дисциплинам, включая общую медицину, психиатрию, пси
...
A guide for training at a village and clinic level
Private sector engagement opens pathways for a game-changing US$2 billion investment opportunity in the fight against HIV, tuberculosis and malaria.
To meet our Strategy objectives and get within reach
of the 2030 SDG 3 target related to the three diseases,
the Global Fund needs to raise US$18 billion for the
Eighth Replenishment. That sum is
...
WHO Ghana 2022 annual report
recommended
“2022 was an eventful year for the WHO Country Office in Ghana,” says Dr Francis Kasolo, WHO Representative to Ghana.
In 2022, WHO Ghana collaborated with partners to deliver interventions in support of the Government of Ghana's health sector
...
Interim guidance, 6 October 2021
Direct detection of SARS-CoV-2 viral proteins (antigens) in nasal swabs and other respiratory secretions using lateral flow immunoassays (also known as rapid diagnostic tests, RDTs) offers a faster
...
The current trend in AMR in Uganda and globally is rising and calls for immediate action. The 71st UN General Assembly (UNGA), the 68th World Healt
...
Fever Diagnostic Technology Landscape
recommended
1st edition.
Unitaid’s report describes a slate of new devices that can more efficiently identify dangerously ill children so that they can be treated immediately. These tools make it easier to recognize danger signs,
...
The portable diagnostic imaging technology covered by this document will serve not only the pressing demands for tuberculosis screening and triage but also other diseases. Therefore, the requirement
...
Core Guidance. Differentiated service delivery is highlighted as a key approach for HIV programmes to enhance implementation quality and efficiency.
This guide provides an overview of the major elements that must be considered before, during and after the implementation of antigen-detecting rapid diagnostic tests (Ag-RDTs) for SARS-CoV-2. This g
...
In April 2020, Gavi and COVAX joined the Access to COVID-19 Tools Accelerator (ACT-A) to provide equitable global access to COVID-19 vaccines to tackle the pandemic. In June 2020, the Gavi COVAX Advance Market Commitment (AMC) was launched to financ
...
The development of this draft Proposed programme budget 2022–2023 comes at a unique moment for WHO. The world is in the grip of the coronavirus disease (COVID-19) pandemic and faces health, social
...
This progress report reflects achievements made during the first year of implementation (through December 2016), as countries have taken actions in line with new or existing national strategies. The most recent data on country progress in 2016 are b
...
The pre-clinical pipeline shows more innovation and diversity, with 252 agents being developed to treat WHO priority pathogens.
However, these products are in the very early stages of development and
...
